Q
QuantAbundanceAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

30,620 signal articles · 84 in last 24h · 155,571 total before filter · latest 58m ago
84last 24h
846last 7d
142● bullish (7d)
90● bearish (7d)
214publishers
AllMacro194Earnings105M&A122Regulatory20Product21Analyst19
✕ clear all filterssentiment: neutralSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
3 Unpopular Stocks Walking a Fine Line
StockStory3d agoneutral
3 Unpopular Stocks Walking a Fine Line

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.

Gadgets Are Going Premium—and Manufacturers Are Raking It In
The Wall Street Journal3d agoneutral
Gadgets Are Going Premium—and Manufacturers Are Raking It In

Apple’s iPhones, for example, are projected by Wall Street analysts to generate 17% more revenue this calendar year, according to FactSet. The main reason for the disconnect between sales and revenue are memory chip prices, which are being driven higher by the AI race.

Cameco And 2 Canadian Nuclear Stocks To Watch
Simply Wall St.3d agoneutral
Cameco And 2 Canadian Nuclear Stocks To Watch

Energy markets are on edge as the Iran conflict disrupts oil supply, and the Federal Reserve keeps lifting interest rates to fight stubborn inflation. Power that is not tied to fossil fuels suddenly matters more to Canadian investors. Nuclear-focused companies sit squarely in that conversation. This article walks through three nuclear energy stocks from the Canadian market that can help you study this theme in a focused and time efficient way. The three nuclear energy stocks covered below are...

What Is Drawing Fresh Attention To D Wave Quantum (QBTS)?
Simply Wall St.3d agoneutral
What Is Drawing Fresh Attention To D Wave Quantum (QBTS)?

D-Wave Quantum (QBTS) has just added veteran financial technology executive Bernard Gavgani to its Board of Directors and Cybersecurity Committee, giving investors a fresh governance angle to assess alongside recent insider selling trends. Recent trading tells a mixed story for D-Wave Quantum. The share price is down 37.58% year to date and 23.59% over 90 days. However, the 7 day share price return of 7.01% hints at short term momentum within a much weaker long term trend, even after a very...

Biogen (BIIB) Posts New Kidney Trial Data, Is It Still 5% Undervalued?
Simply Wall St.3d agoneutral
Biogen (BIIB) Posts New Kidney Trial Data, Is It Still 5% Undervalued?

Biogen (BIIB) is back in focus after publishing adolescent subgroup data from its Phase 3 VALIANT trial of EMPAVELI in rare kidney diseases, a catalyst that gives investors fresh clinical context around the stock. For context, Biogen’s recent clinical and product news has landed against a backdrop of stronger trading action, with a 1-day share price return of 2.87% on the latest close at US$225.36 and a 90-day share price return of 12.91%. Investors are weighing kidney and Alzheimer’s updates...

Pfizer (PFE) Stock May Be Overvalued After Overseas Pricing Deal
Simply Wall St.3d agoneutral
Pfizer (PFE) Stock May Be Overvalued After Overseas Pricing Deal

Pfizer has quietly put together a 23.9% gain over the past year, and that kind of move invites a closer look at whether the current share price lines up with what its earnings can support. With the stock recently closing at US$27.93, the question is how much of the latest news and revenue mix shifts are already reflected in that figure. The 23.9% 1 year return has reset expectations for Pfizer, which puts more weight on whether its earnings base can carry that higher price level. Fresh...

Micron (MU) Stock Looks Reasonable Despite Its Very Large Run
Simply Wall St.3d agoneutral
Micron (MU) Stock Looks Reasonable Despite Its Very Large Run

Micron Technology has turned into one of the market's most eye catching semiconductor stories. The real question for anyone looking at the stock today is whether the current price can be squared with the earnings that sit behind it. After a powerful multi year run and a stream of headline grabbing developments, the key issue now is what investors are actually paying for in terms of profits. Over the past 3 years Micron Technology has delivered a very large share price gain of about 15x. That...

AbbVie (ABBV) Won EU Approval For RINVOQ In Pediatric Arthritis
Simply Wall St.3d agoneutral
AbbVie (ABBV) Won EU Approval For RINVOQ In Pediatric Arthritis

AbbVie (NYSE:ABBV) received European Commission approval for RINVOQ in polyarticular juvenile idiopathic arthritis for patients as young as two. Allergan Aesthetics launched AA Signature SKIN360 in the U.S., offering a multimodal digital platform for medical aesthetics consultations. AbbVie entered AI-focused collaborations with Iambic and the AISB Bind project to use advanced models in drug discovery and molecular binding prediction. The RINVOQ pediatric extension, AA Signature SKIN360...